Madhu Kumar

3 Stocks To Double Down On In 2022

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

Baird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

Baird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset

Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade

Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided'

Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade

Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided'

Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run

3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy

Madhu Kumar Recent News

Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain

B Riley Likes Tocagen On Prospects For Company's Brain Cancer Drug

With Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip

Analyst: Clementia Has Potential To Reach Unmet Market For Rare Bone Disease

Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation

Priority Review For Tetraphase's Eravacycline A 'Key Positive,' Analyst Says

Deciphera Pharma Scores A Sell-Side Recommendation

Alnylam Pharma The New 'Alpha Generator' Stock Pick At FBR

Why Ionis Results Today Support A Pair Trade With Alnylam

Chardan Still Skeptical Of Coversin, Reiterates Sell Rating On Akari Therapeutics

Clovis Shares Reiterated As A Sell Following 10% Rally

Reasons To Stay Bullish On Alnylam In The New Year

For Arbutus' Hepatitis B Treatment, 'Liver Safety Risk Overwhelms Promising Efficacy'

Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space

Arrowhead Pharma Downgraded Following EX-1 RNAi Program Discontinuations

Chardan Recommends Selling Clovis Oncology

Achillion Pharma Initiated At Sell By Chardan, Sees ≥60% Downside

Chardan Analysts Initiate Coverage On Akari Therapeutics With A Sell Rating

ProQR Therapeutics Has Limited Downside Or Upside According to Chardan

Arbutus Biopharma Taken Off Of Chardan's Sell List

Regulus RG-101 Results 'Potentially Breakthrough,' Chardan Says; Target Raised To $20

5 Reasons Arrowhead Pharma Is A Hepatitis B Leader

Analyst Highlights Regulus Therapeutics' 'Disruptive 2016 Catalysts'